Levin discusses a new study, by Meager and colleagues, which identified a novel target of the disordered immune response in patients with APS-1.
No takes yet. Share an insight, caveat, or question.
Michael Levin (2006) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: